Marshall Wace
PVLA

Marshall Wace’s Palvella Therapeutics PVLA Stock Holding History

Marshall Wace’s Portfolio PVLA Stock Details PVLA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$436K Buy
+2,852
New +$346K ﹤0.01% 2578
2026
Q1 		– Sell
-9,484
Closed -$993K – 3775
2025
Q4 		$993K Buy
+9,484
New +$809K ﹤0.01% 1935
2025
Q3 		– Sell
-49,077
Closed -$1.11M – 3522
2025
Q2 		$1.11M Buy
49,077
+18,732
+62% +$440K ﹤0.01% 1802
2025
Q1 		$849K Buy
+30,345
New +$585K ﹤0.01% 1857
2023
Q2 		– Sell
-28,329
Closed -$2.22M – 3055
2023
Q1 		$2.22M Sell
28,329
-1,571
-5% -$182K ﹤0.01% 1399
2022
Q4 		$2.49M Sell
29,900
-615
-2% -$49.4K 0.01% 1612
2022
Q3 		$2.81M Sell
30,515
-1,106
-3% -$143K 0.01% 1793
2022
Q2 		$4.73M Sell
31,621
-847
-3% -$155K 0.01% 1388
2022
Q1 		$7.87M Buy
32,468
+4,921
+18% +$1.29M 0.01% 1048
2021
Q4 		$8.33M Buy
27,547
+24,804
+904% +$7.94M 0.02% 1005
2021
Q3 		$1.13M Buy
2,743
+2,488
+976% +$866K ﹤0.01% 1938
2021
Q2 		$78K Buy
+255
New +$55.9K ﹤0.01% 2554
2020
Q1 		– Sell
-592
Closed -$171K – 2134
2019
Q4 		$171K Buy
+592
New +$164K ﹤0.01% 1375
2018
Q4 		– Sell
-2,013
Closed -$902K – 1849
2018
Q3 		$902K Buy
2,013
+1,721
+589% +$748K 0.01% 834
2018
Q2 		$118K Buy
+292
New +$139K ﹤0.01% 673

Other funds holding PVLA

SCM
Suvretta Capital Management New York $5.47B AUM 131.34% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $167B AUM 44.17% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
FLSM
Frazier Life Sciences Management Palo Alto, California $4.59B AUM 237.58% 1-Year Est. Return
FLAM
First Light Asset Management Edina, Minnesota $1.65B AUM 203.21% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
FCM
Frontier Capital Management Boston, Massachusetts $10.7B AUM 67.78% 1-Year Est. Return

Marshall Wace's PVLA Position: Q2 2026 in Review

Marshall Wace opened a new position in Palvella Therapeutics (PVLA) in Q2 2026: 2,852 shares worth $436K. The stake represents ﹤0.01% of the portfolio and ranks #2578 among its holdings. This is a return to the name: Marshall Wace previously reported a position in PVLA as recently as Q4 2025.

Marshall Wace first reported a position in PVLA in Q2 2018 and has held it in 15 quarters since. The position peaked at $8.33M in Q4 2021. 197 funds tracked by Wall St. Rank hold PVLA as of Q2 2026.

  • Marshall Wace held 2,852 shares of Palvella Therapeutics worth $436K as of Q2 2026.
  • Palvella Therapeutics was a new Marshall Wace position in Q2 2026.
  • Palvella Therapeutics made up ﹤0.01% of Marshall Wace's portfolio in Q2 2026, its #2578 holding.
  • Marshall Wace first reported a position in Palvella Therapeutics in Q2 2018 and has held it in 15 quarters since.
  • Marshall Wace's Palvella Therapeutics position peaked at $8.33M in Q4 2021.
  • 197 funds tracked by Wall St. Rank held Palvella Therapeutics as of Q2 2026.

Based on Marshall Wace's 13F filing for Q2 2026, filed 13 Aug 2026.